FIELD: biotechnology, medicine.
SUBSTANCE: invention represents chimeric antibodies exhibiting specificity with respect to human antigen CD4, DNA encoding thereof and their application as therapeutic agents. These chimeric antibodies comprise sequences of narrow-nosed monkey immunoglobulin variable domain and sequences of human immunoglobulin constant domain. These antibodies show desirable therapeutic properties, among them low antigenicity, reduced (or absence) activity in T-cells exhaustion, good affinity with respect to human CD4 and enhanced stability (half-life time period in body in vivo) and therefore this invention provides the development of more effective method for treatment or prophylaxis of the CD4-associated state.
EFFECT: valuable biological and medicinal properties of antibodies.
30 cl, 25 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT ANTIBODY WITH SPECIFICITY TO CD4, METHOD OF ITS PREPARING AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PATIENTS WITH PSORIASIS | 1992 |
|
RU2170256C2 |
| MONOCLONAL ANTIBODIES AGAINST IL-21 OF HUMAN BEING | 2008 |
|
RU2504552C2 |
| MONOCLONAL ANTIBODIES TO FIBROBLAST GROWTH FACTOR RECEPTOR 2 | 2009 |
|
RU2546254C9 |
| ANTIBODIES SPECIFIC TO BTN2 AND THEIR APPLICATIONS | 2018 |
|
RU2794996C2 |
| HUMANISED ANTIBODIES TO Toll-LIKE RECEPTORS 2 AND THEIR APPLICATIONS | 2010 |
|
RU2563344C2 |
| ANTIBODIES RAISED AGAINST α-INTERFERON | 2002 |
|
RU2314317C2 |
| COMBINED THERAPY FOR TREATMENT OF AUTOIMMUNE DISEASES BY USING COMBINATION OF ELIMINATING B-CELLS AND IMMUNOREGULATORY ANTIBODIES | 2001 |
|
RU2285541C2 |
| ANTIBODIES AGAINST MYELIN-ASSOCIATED GLYCOPROTEIN (MAG) | 2003 |
|
RU2303461C9 |
| INTERLEUKIN-13-BINDING PROTEINS | 2012 |
|
RU2605327C2 |
| IL2 ANTIBODIES | 2006 |
|
RU2425054C2 |
